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BACKGROUND: Vascular endothelial growth factor
(VEGF) family members play a major role in angiogenesis
and vascularization. VEGF-A promotes tumor angiogen-
esis by stimulating the growth of tumor vascular endo-
thelial cells. In addition, VEGF-C has been identified as a
potent inducer of lymphangiogenesis in tumor and lymph
node metastasis. Previous studies have investigated the
association between clinicopathological factors and the
expression of VEGF-A and VEGF-C in oral squamous cell
carcinoma cancer (OSCC), but the results are contradic-
tory. In this study, we investigated the relationship
between VEGF-A and VEGF-C expression and OSCC
clinicopathological factors and prognosis.
METHODS: Expression of VEGF-A and VEGF-C was
evaluated in surgical specimens from 61 patients with
OSCC and three human oral cancer cell lines (OSC-19,
OSC-20 and HOC313) by immunohistochemical staining
and enzyme-linked immunosorbent assay, respectively.
We also determined the relationship between the 5-year
survival rate and clinicopathological factors, such as TNM
classification (Union for International Cancer Control,
UICC), lymph node metastasis, recurrence, histological
differentiation, location, and mode of invasion.
RESULTS: VEGF-A expression correlated significantly
with lymph node metastasis. VEGF-C expression was
associated with lymph node metastasis, recurrence, and a
poorer 5-year survival rate. A multivariate analysis
demonstrated that VEGF-C is an independent prognostic
factor for patients with OSCC. VEGF-C expression was
significantly up-regulated in HOC313 cells compared to
OSC-19 and OSC-20 cells.
CONCLUSIONS: These results indicate that VEGF-C
may be a predictive factor for OSCC outcome, lymph
node metastasis, and recurrence. Moreover, VEGF-C
may be an important factor in the development of new
therapies for OSCC patients.
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Introduction
Oral squamous cell carcinoma (OSCC) is a malignant tumor
found most often in the head and neck region (1, 2). The
presence or absence of lymph node metastasis and the mode
of invasion inﬂuence the outcomes of OSCC patients.
Current treatment regimens are guided by traditional
clinicopathologic factors such as TNM stage, histological
grade, and patient age. Despite efforts over the past two
decades, treatment approaches such as surgery, radiother-
apy, chemotherapy, or combinations of these have had little
effect on the improvement in the survival rate (3); for
example, a reported 5-year survival rate of OSCC patients
was poor (approximately 56%) (2). To improve the
prognoses of OSCC patients, the mechanisms underlying
this cancer’s pathogenesis and progression must be
identiﬁed.
Tumor angiogenesis and lymphangiogenesis play an
essential role in the growth, invasion, and metastatic spread
of solid neoplasms (4). Various angiogenesis factors and the
group of their related factors have signiﬁcant effects on
angiogenesis and lymphangiogenesis. Vascular endothelial
growth factor (VEGF), platelet-derived endothelial cell
growth factor (PD-ECGF), and basic ﬁbroblast growth
factor (bFGF) are the main factors involved in angiogenesis.
The VEGF family members that have been identiﬁed
include VEGF-A, -B, -C, -D, and -E, and the receptors
VEGFR-1, -2, and -3. Among them, VEGF-A promotes
tumor angiogenesis by strongly stimulating the growth of
tumor vascular endothelial cells and chemotactic factor (5),
and it is reported that expression of VEGF-A is related to
tumor progression or poor prognosis in several human
malignancies, including breast cancer (6), lung cancer (7),
gastric cancer (8), pancreatic cancer (9), and prostate cancer
(10). Overexpression of VEGF-A has been reported to be
signiﬁcantly associated with lymph node metastasis, histo-
Correspondence: Koroku Kato, Department of Oral and Maxillofacial
Surgery, Kanazawa University Graduate School of Medical Science, 13-1
Takara-machi, Kanazawa City 920-8640, Ishikawa, Japan. Tel:
+81 76 265 2444, Fax: +81 76 234 4268, E-mail: k-koroku@oral.m.
kanazawa-u.ac.jp
Accepted for publication January 7, 2014
doi: 10.1111/jop.12167
J Oral Pathol Med
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
wileyonlinelibrary.com/journal/jop
logical differentiation, recurrence, and poor prognosis in
head and neck cancer (11). In addition, VEGF-C has been
identiﬁed as a potent inducer of the lymphangiogenesis of
tumor and lymph node metastasis (2, 12, 13). There are
previous studies of the association between clinicopatho-
logical factors and the expressions of VEGF-A and VEGF-
C in oral SCC, but the outcome is controversial. In this
study, we evaluated the expressions of VEGF-A and VEGF-
C in oral SCC and investigated their relationship to
clinicopathological factors and prognosis.
Materials and methods
Tissue samples
The subjects were 61 patients with primary OSCC who
underwent surgical resection at the Department of Oral and
Maxillofacial Surgery at Kanazawa University Hospital
between 1989 and 2007. The tumors’ TNM categories were
classiﬁed according to the Union for International Cancer
Control (UICC) system. The grade of tumor differentiation
was determined according to the criteria proposed by the
World Health Organization. The mode of tumor invasion
was assessed according to the classiﬁcation by Yamamoto
et al. (14). Details of the patient and tumor characteristics
are given in Table 1.
Cell lines
Three human oral squamous cell carcinoma cell lines with
different invasive activities were used: OSC-20, OSC-19
(lower invasive type), and HOC313 (higher invasive type).
OSC-20 is a cell line derived a 58-year-old female with
metastatic tongue cancer to the cervical lymph nodes (15).
OSC-19 was derived from a 61-year-old male with meta-
static tongue cancer to the cervical lymph node (16).
HOC313 was derived from a 51-year-old female with
metastatic squamous cell carcinoma (involving the mandib-
ular gingival and oral ﬂoor) to the cervical lymph nodes
(17). In addition, the normal human dermal ﬁbroblast line
(NHDF) was used as control.
Immunohistochemical staining
Tissue specimenswereﬁxed in 10%neutral buffered formalin
and embedded in parafﬁn; then, 4-mm-thick sections were
cut. Immunohistochemical detection of VEGF-A and VEGF-
C was performed using an anti-VEGF-A rabbit polyclonal
antibody at 1:200 dilution (LifeSpan BioScience, Seattle,
WA, USA) and anti-VEGF-C rabbit polyclonal antibody at
1:100 dilution (Life Technologies, Carlsbad, CA, USA),
respectively. Tissue sections were deparafﬁnized with xylene
and rehydrated in graded alcohol. Endogenous peroxidase
was blocked by treatment with 0.3% hydrogen peroxide in
methanol for 30 min and incubated with the primary
antibodies at 4°C overnight. Bound antibody was detected
using the Envision system (Dako, Carpinteria, CA, USA).
Diaminobenzidine (1 mg/ml) in the presence of 0.03%
hydrogen peroxidase was used to visualize any bound
peroxidase, and sections were counterstained with hematox-
ylin. The speciﬁcities of the staining were conﬁrmed by using
non-immune serum instead of the primary antibody as a
negative control. The expressions of VEGF-A and VEGF-C
were evaluated with immunohistochemically stained prepa-
rations using anti-VEGF-A antibody and anti-VEGF-C
antibody. Immunohistochemical evaluation was carried out
in accord with the report of Takanashi (18). The staining
intensity of tumor cells in the leading invasion front regions
was classiﬁed into four groups (0: none, 1: mild, 2: moderate,
3: strong), and cases were considered positive if their staining
intensity was 2 or 3.
Enzyme-linked immunosorbent assay
For enzyme-linked immunosorbent assay analysis of
VEGF-A and VEGF-C, supernatant of cultured several
human oral cancer cell lines (OSC-19, OSC-20 and
HOC313) and human normal dermal ﬁbroblast cell lines
(NHDF) were used. The supernatant was collected from
cultured each cell line for 24 h. The concentrations of
VEGF-A and VEGF-C were determined using ELISA kits
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s protocols.
Statistical analysis
JMP 9 (SAS Institute Inc., Cary, NC, USA) was used for
data analysis. The relationships between the expression of
these proteins and clinicopathological parameters were
examined by the chi-square test. We calculated the 5-year
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survival rates by the Kaplan–Meier method and compared
them using the log-rank test. Factors found to be signiﬁcant
were then chosen for Cox’s multivariate proportional hazard
model in order to ascertain their prognostic values. The
signiﬁcance level was set at 5% for each analysis. The data
of ELISA are presented as the mean values SEM. The
differences between groups were tested for statistical
signiﬁcance using the two-tailed Mann–Whitney U test.
P-values <0.05 were considered statistically signiﬁcant.
Results
Expression of VEGF-A and VEGF-C in oral SCC
VEGF-A and VEGF-C were detected in the cytoplasm of
tumor cells (Figs 1 and 2). According to the criteria for
VEGF immunohistochemical evaluation, 46 cases (75.4%)
were positive for VEGF-A, and 24 cases (39.3%) were
positive for VEGF-C.
Association between VEGF-A or VEGF-C expression and
clinicopathological features
Table 2 displays the correlations between VEGF-A and
VEGF-C expression and the patients’ clinicopathological
factors. VEGF-A expression was signiﬁcantly correlated
with lymph node metastasis (P < 0.05) but was not corre-
lated with tumor size, local recurrence, histological differen-
tiation, or mode of invasion. VEGF-C expression was
signiﬁcantly correlated with lymph node metastasis and local
recurrence (P < 0.05) but was not correlated with tumor size,
histological differentiation, location, or mode of invasion.
Correlations between VEGF-A or VEGF-C expression and
survival time
Figure 3 shows the Kaplan–Meier survival curves of the
VEGF-A-positive and VEGF-C-positive groups compared
to their negative group counterparts. The 5-year survival
rate was 57.6% for the VEGF-A-positive group and 72.7%
for the VEGF-A-negative group (Fig. 3A). The VEGF-A-
positive group showed low survival rates, but there was no
signiﬁcant difference in survival compared with the negative
group (Fig. 3A). The 5-year survival rate was 41.2% for the
VEGF-C-positive group and 81.2% for the VEGF-C-
negative group (Fig. 3B). The VEGF-C-positive group
showed signiﬁcantly poorer prognoses compared to the





Figure 1 Immunohistochemical stain of Vascular endothelial growth factor-A (VEGF-A) in squamous cell carcinoma (A–D) and normal oral tissue (E, F).
According to the expression intensity of VEGF-A, the samples are differentiated as positive (A) and negative (C) groups. The speciﬁcities of the staining
were conﬁrmed by using non-immune serum instead of the primary antibody as a negative control (B, D and F). Scale bar, 100 lm.
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Cox proportional hazards regression analysis of the
predictive factors for prognosis
We performed a Cox proportional hazards regression
analysis to examine the signiﬁcance of the predictive
factors. A univariate analysis revealed that the expression
of VEGF-C and the mode of invasion were signiﬁcant
prognostic indicators, but not VEGF-A. In addition, a
multivariate analysis showed that VEGF-C expression and
the mode of invasion were independent prognostic factors
(Table 3).
Expression of VEGF-A or VEGF-C in human oral cancer
cell lines
As demonstrated by the immunohistochemical analysis, the
number of cancer cells expressed VEGF-A and VEGF-C.
Therefore, we further examined several human oral SCC
lines (OSC-19, OSC-20, and HOC313) with different
invasive activities by measuring the concentration of the
expressed VEGF-A and VEGF-C. The VEGF-A expression
of OSC-19 (126.1  20.92 pg/mg protein), OSC-20
(121.5  4.66 pg/mg protein), and HOC313 (153.1 
19.7 pg/mg protein) was signiﬁcantly up-regulated compare
to NHDF (0.2  0.68 pg/mg protein) (mean  SEM,
Fig. 4). However, there was no signiﬁcant difference
between OSC-19, OSC-20, and NHDF. On the other hand,
the VEGF-C expression of HOC313 (337.8  23.8 pg/mg
protein) was signiﬁcantly up-regulated compare to OSC-19
and OSC-20 (210.8  64.2, 196.6  56.7 pg/mg protein)
(mean  SEM, Fig. 4). There was no signiﬁcant difference
between OSC-19 and OSC-20. The VEGF-C expression
levels of three oral cancer cells were signiﬁcantly higher
compared with NHDF (66.7  8.84 pg/mg protein)
(mean  SEM, Fig. 4).
Discussion
VEGF-A is a key tumor-derived growth factor that
promotes the switch to an angiogenic phenotype in many
tumors and other tissues. Interestingly, our study shows that
the expression of VEGF-A is correlated with lymph node
metastasis. This is most likely because VEGF-A can bind to
VEGFR-1 and VEGFR-2, but not to VEGFR-3, which is
expressed in lymphatic endothelial cells. Several studies







Figure 2 Immunohistochemical stain of Vascular endothelial growth factor-C (VEGF-C) in squamous cell carcinoma (A–D) and normal oral tissue (E, F).
According to the expression intensity of VEGF-C, the samples are differentiated as positive (A) and negative (C) groups. The speciﬁcities of the staining were
conﬁrmed by using non-immune serum instead of the primary antibody as a negative control (B, D and F). Scale bar, 100 lm.
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(19, 20). Other groups have demonstrated that VEGF-A
expression is associated with lymph node metastasis (11, 21,
22). A recent study reported that the VEGFR-2 receptor is
occasionally expressed on lymphatic endothelial cells (23).
Unlike VEGFR-2, the afﬁnity of VEGFR-1 for its ligand,
VEGF-A, is approximately one order of magnitude higher
than that of VEGFR-2. However, the kinase activity of
VEGFR-1 is lower than VEGFR-2 (about one-tenth that of
VEGFR-2), so VEGF-A is thought to act mainly through the
activation of VEGFR-2 (3, 23–25). These data suggest that
VEGF-A may have a direct stimulatory effect on lymphatic
vessels in OSCC.
VEGF-C expression has been detected in a variety of
tumors (26–29). VEGF-C, which binds to VEGFR-3, is
known to be a major factor in lymphangiogenesis (30, 31).
VEGF-C binds to VEGFR-3 on the surface of lymphatic
endothelial cells, inducing the proliferation and growth of
new lymphatic vessels and leading to tumor cell dissemi-
nation and lymph node metastasis (2, 11, 32). VEGF-C
expression is associated with lymphatic vessel density (31,
33, 34) and lymph node metastases (30, 31, 35) in oral
cancer. Pentheroudakis et al. (36) also reported an associ-
ation between local recurrence and VEGF-C expression in
head and neck cancer. In this study, we show that VEGF-C
expression is associated with lymph node metastasis in
OSCC. We also observed an association between VEGF-C
expression and local recurrence. The data in this study are
consistent with previous reports. However, further studies
are needed to understand the precise role of VEGF-C in
local recurrence.
There was no signiﬁcant difference in the 5-year survival
rate between patients from the VEGF-A-positive group and
the VEGF-A-negative group. In contrast, the survival rate of
the VEGF-C-positive group was signiﬁcantly decreased
compared to the VEGF-C-negative group. The results of our
analysis using a Cox proportional hazards model show that
the mode of invasion and VEGF-C expression are indepen-
dent prognostic factors. Our ELISA data show that VEGF-C
expression is signiﬁcantly higher in a highly invasive cell
line (HOC313) than in cell lines with lower invasiveness
(OSC-19 and OSC-20). Highly invasive OSCC is closely
related to the prognosis (14). These results suggest that
VEGF-C may affect OSCC prognosis. The clinicopatho-
logical factors currently used to predict metastasis and
prognosis include TNM classiﬁcation, degree of differenti-
ation, and mode of invasion. We propose including a
molecular biological factor for comprehensive diagnoses in
the future. More complete diagnostic methods not only
improve the accuracy of diagnosing metastases, but could
also help determine the prognosis and facilitate decision-
Table 2 Correlations between the expressions of vascaular endothelial
growth factor-A, -C (VEGF-A, VEGF-C), and the oral squamous cell
















T1 12 4 5 11
T2 29 8 15 22
T3 1 0 0.623 1 0 0.564
T4 4 3 3 4
Lymph node metastasis
Present 9 7 0.038 10 6 0.027
Absent 37 8 14 31
Recurrence
Yes 16 2 0.113 13 5 0.0006
No 30 13 11 32
Histologic differentiation
Well 33 9 0.222 16 26 0.997
Moderate 8 4 5 7




6 0 0.221 2 4 0.627
Gingiva 14 5 8 11
Tongue 23 7 13 17
Oral
ﬂoor
3 2 1 4
Paratal
mucosa
0 1 0 1
Mode of invasion (Y-K)
1 2 2 1 3
2 12 1 6 7
3 15 4 0.206 6 13 0.734
4C 11 7 7 11





















































Figure 3 (A) The Kaplan–Meier survival rate of the VEGF-A-positive
group shows low survival, but there was no signiﬁcant difference in
survival compared with the VEGF-A-negative group (P = 0.6918). (B) The
VEGF-C-positive group showed signiﬁcantly poorer prognoses compared
to the VEGF-C-negative group (P = 0.029).
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making regarding the necessity of prophylactic neck
dissection. Our results suggest that VEGF-C may be a
predictive factor for OSCC outcome.
Recently, new therapies have been developed to target
VEGF-A. However, resistance to anti-angiogenic therapies
limits the clinical beneﬁt of these agents in cancer patients.
The single-agent response rate to anti-angiogenic drugs such
as bevacizumab (a monoclonal antibody to VEGF-A) is
<10%, and even in patients who do respond, the duration of
the response is typically <3 months (37–39). Similar
response rates are observed in head and neck squamous
cell carcinomas (40), for which bevacizumab is being
evaluated in phase III clinical trials. Our results suggest that
therapies targeting VEGF-C may be expected to play a
major role in the treatment of bevacizumab-resistant OSCC
in the future.
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